MAIA Biotechnology (MAIA) Expands Phase 3 THIO-104 Trial to Spain and Portugal
MAIA Biotechnology received approvals in Spain and Portugal to begin screening for its pivotal Phase 3 THIO-104 NSCLC trial, targeting ~100 patients dosed by year-end 2026 and an interim survival analysis expected in 2027.Material DetailsContext by AI AnalystThis is an execution update on MAIA’s pi…